title: Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
abstract: BACKGROUND
  Intravitreal injections of bevacizumab have been reported to have anatomical and functional success in treating choroidal neovascularization, macular edema and neovascular glaucoma. We report a case with neovascular glaucoma due to central retinal vein occlusion who demonstrates rapid resolution of anterior and posterior segment neovascularization after a single intravitreal bevacizumab injection.
  
  
  METHODS
  A 46-year old man with a 6-month history of central retinal vein occlusion presented with neovascular glaucoma. Fluorescein angiography revealed marked leakage from new vessels on the iris, disc and retina. Bevacizumab was used after incomplete panretinal photocoagulation because of inadequate fundus visualization. About a week after intravitreal bevacizumab injection, new vessels were no longer visible. IOP improved and additional laser photocoagulation was performed.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab injection may be a useful alternative or adjuvant treatment for patients with neovascular glaucoma in whom inadequate visualization precludes adequate panretinal photocoagulation.
authors.affiliation: Department of Ophthalmology, Ankara University School of Medicine, Mamak yolu, Dikimevi, 06100, Ankara, Turkey. fbatioglu@gmail.com
authors.forename: Figen
authors.initials: F
authors.lastname: Batioğlu
authors.forename: Neslihan
authors.initials: N
authors.lastname: Astam
authors.forename: Emin
authors.initials: E
authors.lastname: Ozmert
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005451:Fluorescein Angiography; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D007498:Iris / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000209:etiology; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab